Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25921453 | 0.92 | MEN1 (0.41) | MEN1KMT2AGLP1RTSHRLMNA | |
| SCHEMBL25921460 | 0.90 | MEN1 (0.44) | MEN1KMT2AGLP1RTSHRLMNA | |
| SCHEMBL24673214 | 0.90 | MEN1 (0.44) | MEN1KMT2AGLP1RADORA1 | |
| SCHEMBL21539584 | 0.88 | MEN1 (0.42) | MEN1KMT2AGLP1RTSHRLMNA | |
| SCHEMBL23806113 | 0.87 | MEN1 (0.46) | MEN1KMT2AGLP1RADORA1 | |
| SCHEMBL24672594 | 0.87 | MEN1 (0.38) | MEN1KMT2AGLP1RTSHRADORA1 | |
| SCHEMBL22861621 | 0.83 | MEN1 (0.42) | MEN1KMT2AGLP1R | |
| SCHEMBL25924806 | 0.82 | MEN1 (0.46) | MEN1KMT2AGLP1RTSHRLMNA | |
| SCHEMBL25697756 | 0.80 | MEN1 (0.36) | MEN1KMT2AGLP1RTSHRMAPK1 | |
| SCHEMBL23696502 | 0.80 | MEN1 (0.46) | MEN1KMT2AGLP1RTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885GLP1R 2955/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885GLP1R 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.